SLPI and prostate cancer: found that androgen receptor can alter the metastasis of prostate and bladder cancer through changing the expression of the vasculogenic mimicry biomarker SLPI by miR-525-5p; therefore, targeting the androgen receptor–miR-525-5p-SLPI axis may be a strategy to suppress prostate cancer metastasis (19).